17,893 Shares in Fresenius Medical Care AG (NYSE:FMS) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new stake in Fresenius Medical Care AG (NYSE:FMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 17,893 shares of the company's stock, valued at approximately $405,000.

A number of other hedge funds have also recently added to or reduced their stakes in FMS. Wilmington Savings Fund Society FSB acquired a new stake in shares of Fresenius Medical Care during the third quarter worth $38,000. Franklin Resources Inc. grew its stake in shares of Fresenius Medical Care by 3.3% in the 3rd quarter. Franklin Resources Inc. now owns 74,640 shares of the company's stock worth $1,490,000 after acquiring an additional 2,386 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Fresenius Medical Care by 18.2% in the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company's stock valued at $211,000 after acquiring an additional 1,528 shares in the last quarter. Franklin Street Advisors Inc. NC bought a new position in Fresenius Medical Care during the fourth quarter valued at about $201,000. Finally, Crossmark Global Holdings Inc. increased its position in Fresenius Medical Care by 2.2% in the fourth quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company's stock worth $1,456,000 after buying an additional 1,398 shares during the last quarter. Institutional investors own 8.37% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on FMS shares. StockNews.com raised shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Truist Financial lifted their price target on Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a research note on Monday.

Fresenius Medical Care Stock Performance

Shares of NYSE FMS traded down $0.30 during trading on Monday, hitting $28.09. The company had a trading volume of 245,386 shares, compared to its average volume of 321,761. Fresenius Medical Care AG has a 12 month low of $17.93 and a 12 month high of $28.59. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The firm has a market capitalization of $16.48 billion, a P/E ratio of 23.21, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85. The stock has a 50 day simple moving average of $24.55 and a 200 day simple moving average of $23.45.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The firm had revenue of $5.54 billion during the quarter, compared to analyst estimates of $4.71 billion. As a group, analysts anticipate that Fresenius Medical Care AG will post 1.51 earnings per share for the current year.

Fresenius Medical Care Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 23rd will be issued a $0.7871 dividend. This represents a yield of 1.9%. This is a positive change from Fresenius Medical Care's previous annual dividend of $0.44. The ex-dividend date is Friday, May 23rd. Fresenius Medical Care's dividend payout ratio is presently 49.11%.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.